Literature DB >> 19727147

Prostate cancer: quality of life after radiation and androgen deprivation.

Danil V Makarov, David F Penson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19727147     DOI： 10.1038/nrurol.2009.168

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.

Authors:  David G McLeod; William A See; Ira Klimberg; Donald Gleason; Gerald Chodak; James Montie; Gregory Bernstein; Clive Morris; Jonathon Armstrong
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

2.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

Authors:  Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-31       Impact factor: 7.038

Review 3.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Authors:  D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

4.  A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment.

Authors:  P C Walsh; T L DeWeese; M A Eisenberger
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

5.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.

Authors:  Michael J Zelefsky; Heather Chan; Margie Hunt; Yoshiya Yamada; Alison M Shippy; Howard Amols
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

6.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.

Authors:  Per Fransson; Jo-Asmund Lund; Jan-Erik Damber; Olbjörn Klepp; Fredrik Wiklund; Sophie Fosså; Anders Widmark
Journal:  Lancet Oncol       Date:  2009-03-13       Impact factor: 41.316

8.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Authors:  Anthony V D'Amico; Judith Manola; Marian Loffredo; Andrew A Renshaw; Alyssa DellaCroce; Philip W Kantoff
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

9.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

10.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.